05-07

2022

HealZen and PTM Biolabs Have Reached Strategic Cooperation to Develop Targeted Protein Degradation Drugs

HealZen Therapeutics (‘HealZen’) and PTM Biolabs Co., Ltd. (‘PTM BIO’) have recently reached a strategic partnership agreement to establish a long-term comprehensive strategic partnership in the field of targeted protein degradation (TPD) target discovery, drug development, and other aspects.

01-18

2022

HealZen Announces the Dosing of the First Patient in Phase I Clinical Trial of HZ-H08905 Tablets

HealZen Therapeutics has successfully completed the first patients enrollment for Phase I clinical trial of the innovative drug HZ-H08905, which was independently developed by the company. The trial was conducted at the First Affiliated Hospital, Zhejiang University School of Medicine. This is the first in-human clinical trial of HZ-H08905, which aims to evaluate its safety/tolerability, pharmacokinetic characteristics, and preliminary efficacy in the treatment of relapsed or refractory non-Hodgkin's lymphoma patients.